Allele-Specific Disparity in Breast Cancer Fatemeh Kaveh1, Hege Edvardsen1, Anne-Lise Børresen-Dale1,2, Vessela N Kristensen1,2,3* and Hiroko K Solvang1,4

Total Page:16

File Type:pdf, Size:1020Kb

Allele-Specific Disparity in Breast Cancer Fatemeh Kaveh1, Hege Edvardsen1, Anne-Lise Børresen-Dale1,2, Vessela N Kristensen1,2,3* and Hiroko K Solvang1,4 Kaveh et al. BMC Medical Genomics 2011, 4:85 http://www.biomedcentral.com/1755-8794/4/85 RESEARCHARTICLE Open Access Allele-specific disparity in breast cancer Fatemeh Kaveh1, Hege Edvardsen1, Anne-Lise Børresen-Dale1,2, Vessela N Kristensen1,2,3* and Hiroko K Solvang1,4 Abstract Background: In a cancer cell the number of copies of a locus may vary due to amplification and deletion and these variations are denoted as copy number alterations (CNAs). We focus on the disparity of CNAs in tumour samples, which were compared to those in blood in order to identify the directional loss of heterozygosity. Methods: We propose a numerical algorithm and apply it to data from the Illumina 109K-SNP array on 112 samples from breast cancer patients. B-allele frequency (BAF) and log R ratio (LRR) of Illumina were used to estimate Euclidian distances. For each locus, we compared genotypes in blood and tumour for subset of samples being heterozygous in blood. We identified loci showing preferential disparity from heterozygous toward either the A/B-allele homozygous (allelic disparity). The chi-squared and Cochran-Armitage trend tests were used to examine whether there is an association between high levels of disparity in single nucleotide polymorphisms (SNPs) and molecular, clinical and tumour-related parameters. To identify pathways and network functions over-represented within the resulting gene sets, we used Ingenuity Pathway Analysis (IPA). Results: To identify loci with a high level of disparity, we selected SNPs 1) with a substantial degree of disparity and 2) with substantial frequency (at least 50% of the samples heterozygous for the respective locus). We report the overall difference in disparity in high-grade tumours compared to low-grade tumours (p-value < 0.001) and significant associations between disparity in multiple single loci and clinical parameters. The most significantly associated network functions within the genes represented in the loci of disparity were identified, including lipid metabolism, small-molecule biochemistry, and nervous system development and function. No evidence for over- representation of directional disparity in a list of stem cell genes was obtained, however genes appeared to be more often altered by deletion than by amplification. Conclusions: Our data suggest that directional loss and amplification exist in breast cancer. These are highly associated with grade, which may indicate that they are enforced with increasing number of cell divisions. Whether there is selective pressure for some loci to be preferentially amplified or deleted remains to be confirmed. Background alternations (CNAs) [1]. Such chromosomal variations Higher organisms such as humans are diploid, which have been associated with genetic disorders (for CNVs) means that all chromosomes except the sex chromo- and the progression of cancer (for CNAs) [2]. The size somes are present in two copies (2 n). During DNA of CNVs in normal tissues is often shorter than CNAs replication, unique genomic segments of original DNA in tumour tissues, which can cover a large region of the are normally copied just one time, but in specific situa- human genome (Mb) [3]. Array-based comparative tions, these fragments are either not replicated entirely genomic hybridization (CGH) is used for detection of ortheyarecopiedmorethanonce.Thevariation CNVs and CNAs [4,5]. between normal and actual copy number of a DNA seg- Recently, new techniques have been developed to ment is referred to as copy number differences, which studyCNVsandCNAsatahigherresolutionusing in normal cells are referred to as copy number varia- high-density arrays of single nucleotide polymorphisms tions (CNVs) and in tumour cells as copy number (SNPs) [6]. SNPs are variations in the single-base locus of the genome within members of a species or paired * Correspondence: [email protected] chromosomes of an individual. In general, SNPs have 1Department of Genetics, Institute for Cancer Research, Norwegian Radium precise positions on the chromosome and two alleles Hospital, Oslo University Hospital, Oslo, Norway (maternal and paternal), and SNP-based arrays are Full list of author information is available at the end of the article © 2011 2011 Kaveh et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Kaveh et al. BMC Medical Genomics 2011, 4:85 Page 2 of 13 http://www.biomedcentral.com/1755-8794/4/85 powerful tools for detection of allele-specific chromoso- Human-1 109K BeadChip array (Illumina, San Diego, mal aberrations and loss of heterozygocity (LOH) status CA, USA). For each sample, the corresponding log R [7]. Recent advances in the systematic study of genomic ratio (LRR) and B allele frequency (BAF) were extracted alterations in human cancer samples have made it possi- for both blood and tumour using the Illumina Beadstu- ble to understand this disease better and identify key dio Genotyping software, which is based on the transfor- genes with underlying roles in oncogenesis [8]. In the mation of two channels’ allelic intensity values [7]. present study, we describe the development of a numer- Briefly Illumina’s Beadstudio software performs normali- ical algorithm based on Euclidian distances to extract zation on the two raw allelic intensity values (X, Y)for the maximum level of information from SNP array data each locus (SNP). X and Y values are respectively in blood-tumour pairs, with regard to both chromoso- denoted as allele A and allele B. The normalized allele mal aberrations and loss of heterozygosity. We apply the intensities are transformed to total signal intensity, R (R algorithmtoIllumina109KSNParraydataandshow = X + Y), and relative allelic signal intensity ratio, theta how it can be used to mine information on a single- (θ =arctan(Y/X)(2/π)) [12].Illumina provides two sup- SNP, cytogenic region as well as in gene lists and at the plementary parameters, LRR and BAF,whichreferto pathway level. We focus on the disparity of CNAs in the normalized and calibrated form of R and θ.BAF tumour samples, which were compared to those in represents the proportion of one SNP allele (B)tothe blood in order to identify the directional loss of total number of A and B alleles (NB/(NA + NB)) for each heterozygosity. given loci. The Illumina Infinium platform detects chro- mosomal aberrations by comparing the normalized Methods intensity of a subject sample and a reference sample Materials using two modes of analysis: 1) a single-sample mode, The 112 samples used here are a subset of a larger which derives reference values from canonical genotyp- patient series consisting of 920 samples, which were col- ing clusters (0, 0.5, 1) created from clustering on normal lected from breast cancer patients to study the effect of reference samples; 2) Paired-sample mode, which makes disseminating tumour cells to the blood and bone mar- intensity (R) comparisons between a subject sample and row [9]. The samples were collected at five different hos- its paired reference sample. Genomic plots of LRR (LRR pitals in the Oslo region and have so far been extensively =log2(Rsubject/Rreference)) and BAF of the three canonical studied on both the clinical and biological levels [9,10]. clusters are used to detect chromosomal aberrations [1,13,14]. Comparing custom-clustered data to HapMap- DNA isolation clustered data, we observe improved scoring using cus- Tumour tissues were snap-frozen at -80°C. Samples of tom clustering. The genotypes for both blood and mononucleus peripheral blood cells were drawn in tubes tumour were therefore extracted using custom cluster- and centrifuged. Before freezing, the cell pellet was ing [15]. To improve the results of genotyping for those resuspended to a concentration of 30 × 106 cells/ml in a samples that have not performed well, we used the cus- freezing solution containing RPMI added with 10% tom-clustered data. DMSO and 20% FCS as well as Dnase. The samples Missing values are denoted as NaN for both BAF and were then frozen at -70°C before being stored in liquid LRR. Updated SNP information (position and gene asso- nitrogen. Before DNA isolation, 240 μlProt.K(AB- ciation) was derived when available using the UCSC Applied Biosystems) and 400 μl 1 × PBS without CaMg Genome Browser (Human Mar. 2006 Assembly were added to the frozen samples on ice. The samples (NCBI36/hg18)) [16], dbSNP (build 130), Ensembl gen- were incubated at 55°C until thawed and then trans- ome browser (Ensembl genes 57 database on Homo ferred after mixing to the vessels in the Applied Biosys- sapiens genes (GRCh37) dataset) [17], and CHIP Bioin- tems 340A Nucleic Acid Extractor. The remaining formatics Tools, Goldenpath: hg18, dbSNP: build 130 process of DNA isolation followed the standard proce- [18]. dures for the extractor using a phenol-chloroform based method. DNA from frozen tumour tissue was extracted Description of computational algorithm according to standard procedures of the Applied Biosys- Pre-processing of data tems 340A Nucleic Acid Extractor. Traditional Array CGH provides information on CNAs All patients provided informed consent, and the study based on the Log R intensity ratios. The benefit of the was approved by the local regional ethical committees. Illumina SNP array analysis is that it provides additional information related to B allele frequency. The Beadstu- Genotyping dio software presents information, based on two allelic The genotyping used has been previously described [11], intensity values, related to both Log R ratio and B allele and blood-tumour pairs were genotyped using the frequency. To analyze the Illumina output, we propose a Kaveh et al. BMC Medical Genomics 2011, 4:85 Page 3 of 13 http://www.biomedcentral.com/1755-8794/4/85 computational algorithm consisting of the following 1 n steps for each chromosome (illustrated by the flowchart deviation(S = (b − μ )2).
Recommended publications
  • Centromere RNA Is a Key Component for the Assembly of Nucleoproteins at the Nucleolus and Centromere
    Downloaded from genome.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Letter Centromere RNA is a key component for the assembly of nucleoproteins at the nucleolus and centromere Lee H. Wong,1,3 Kate H. Brettingham-Moore,1 Lyn Chan,1 Julie M. Quach,1 Melisssa A. Anderson,1 Emma L. Northrop,1 Ross Hannan,2 Richard Saffery,1 Margaret L. Shaw,1 Evan Williams,1 and K.H. Andy Choo1 1Chromosome and Chromatin Research Laboratory, Murdoch Childrens Research Institute & Department of Paediatrics, University of Melbourne, Royal Children’s Hospital, Parkville 3052, Victoria, Australia; 2Peter MacCallum Research Institute, St. Andrew’s Place, East Melbourne, Victoria 3002, Australia The centromere is a complex structure, the components and assembly pathway of which remain inadequately defined. Here, we demonstrate that centromeric ␣-satellite RNA and proteins CENPC1 and INCENP accumulate in the human interphase nucleolus in an RNA polymerase I–dependent manner. The nucleolar targeting of CENPC1 and INCENP requires ␣-satellite RNA, as evident from the delocalization of both proteins from the nucleolus in RNase-treated cells, and the nucleolar relocalization of these proteins following ␣-satellite RNA replenishment in these cells. Using protein truncation and in vitro mutagenesis, we have identified the nucleolar localization sequences on CENPC1 and INCENP. We present evidence that CENPC1 is an RNA-associating protein that binds ␣-satellite RNA by an in vitro binding assay. Using chromatin immunoprecipitation, RNase treatment, and “RNA replenishment” experiments, we show that ␣-satellite RNA is a key component in the assembly of CENPC1, INCENP, and survivin (an INCENP-interacting protein) at the metaphase centromere.
    [Show full text]
  • 4P Duplications
    4p Duplications rarechromo.org Sources 4p duplications The information A 4p duplication is a rare chromosome disorder in which in this leaflet some of the material in one of the body’s 46 chromosomes comes from the is duplicated. Like most other chromosome disorders, this medical is associated to a variable extent with birth defects, literature and developmental delay and learning difficulties. from Unique’s 38 Chromosomes come in different sizes, each with a short members with (p) and a long (q) arm. They are numbered from largest to 4p duplications, smallest according to their size, from number 1 to number 15 of them with 22, in addition to the sex chromosomes, X and Y. We a simple have two copies of each of the chromosomes (23 pairs), duplication of 4p one inherited from our father and one inherited from our that did not mother. People with a chromosome 4p duplication have a involve any other repeat of some of the material on the short arm of one of chromosome, their chromosomes 4. The other chromosome 4 is the who were usual size. 4p duplications are sometimes also called surveyed in Trisomy 4p. 2004/5. Unique is This leaflet explains some of the features that are the same extremely or similar between people with a duplication of 4p. grateful to the People with different breakpoints have different features, families who but those with a duplication that covers at least two thirds took part in the of the uppermost part of the short arm share certain core survey. features. References When chromosomes are examined, they are stained with a dye that gives a characteristic pattern of dark and light The text bands.
    [Show full text]
  • Identification of Candidate Genes and Pathways Associated with Obesity
    animals Article Identification of Candidate Genes and Pathways Associated with Obesity-Related Traits in Canines via Gene-Set Enrichment and Pathway-Based GWAS Analysis Sunirmal Sheet y, Srikanth Krishnamoorthy y , Jihye Cha, Soyoung Choi and Bong-Hwan Choi * Animal Genome & Bioinformatics, National Institute of Animal Science, RDA, Wanju 55365, Korea; [email protected] (S.S.); [email protected] (S.K.); [email protected] (J.C.); [email protected] (S.C.) * Correspondence: [email protected]; Tel.: +82-10-8143-5164 These authors contributed equally. y Received: 10 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Simple Summary: Obesity is a serious health issue and is increasing at an alarming rate in several dog breeds, but there is limited information on the genetic mechanism underlying it. Moreover, there have been very few reports on genetic markers associated with canine obesity. These studies were limited to the use of a single breed in the association study. In this study, we have performed a GWAS and supplemented it with gene-set enrichment and pathway-based analyses to identify causative loci and genes associated with canine obesity in 18 different dog breeds. From the GWAS, the significant markers associated with obesity-related traits including body weight (CACNA1B, C22orf39, U6, MYH14, PTPN2, SEH1L) and blood sugar (PRSS55, GRIK2), were identified. Furthermore, the gene-set enrichment and pathway-based analysis (GESA) highlighted five enriched pathways (Wnt signaling pathway, adherens junction, pathways in cancer, axon guidance, and insulin secretion) and seven GO terms (fat cell differentiation, calcium ion binding, cytoplasm, nucleus, phospholipid transport, central nervous system development, and cell surface) which were found to be shared among all the traits.
    [Show full text]
  • AL SERAIHI, a Phd Final 010519
    The Genetics of Familial Leukaemia and Myelodysplasia __________________ Ahad Fahad H Al Seraihi A thesis submitted for the Degree of Doctor of Philosophy (PhD) at Queen Mary University of London January 2019 Centre for Haemato-Oncology Barts Cancer Institute Charterhouse Square London, UK EC1M 6BQ Statement of Originality Statement of Originality I, Ahad Fahad H Al Seraihi, confirm that the research included within this thesis is my own work or that where it has been carried out in collaboration with, or supported by others, that this is duly acknowledged below and my contribution indicated. Previously published material is also acknowledged below. I attest that I have exercised reasonable care to ensure that the work is original, and does not to the best of my knowledge break any UK law, infringe any third party’s copyright or other Intellectual Property Right, or contain any confidential material. I accept that the College has the right to use plagiarism detection software to check the electronic version of the thesis. I confirm that this thesis has not been previously submitted for the award of a degree by this or any other university. The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author. Signature: Date: 30th January 2019 2 Details of Collaborations and Publications Details of Collaborations: Targeted deep sequencing detailed in Chapter 3 was carried out at King’s College Hospital NHS Foundation Trust, London, UK, in the laboratory for Molecular Haemato- Oncology led by Dr Nicholas Lea and bioinformatics analysis was performed by Dr Steven Best.
    [Show full text]
  • The Human Gene Encoding Phosphatidylinositol-3 Kinase Associated P85a Is at Chromosome Region 5Ql2-13'
    [CANCER RESEARCH 5l. .1818-.1820, July 15, 1991| Advances in Brief The Human Gene Encoding Phosphatidylinositol-3 Kinase Associated p85a Is at Chromosome Region 5ql2-13' L. A. Cannizzaro, E. Y. Skolnik, B. Margolis, C. M. Croce, J. Schlesinger, and K. Huebner2 Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140 [L. A. C., C. M. C., K. H.J, and Department of Pharmacology, New York University Medical Center, New York, New York 10016 [E. Y. S., B. M., J. S.J Abstract scribed previously (10, 11). Hybrids 9142 (full name GM9142), 114 (GM100114), 115 (GM100115), 7297 (GM7297), 7300 (GM7300), I In' human chromosomal location of the gene encoding the phospha- 449 (GM10449), 10095 (GM10095), and 7301 (GM7301) were ob tidylinositol-3 kinase associated protein, p85a, has been determined by tained from the National Institute of General Medical Sciences Human analysis of its segregation in rodent-human hybrids and by chromosome Genetic Mutant Cell Repository (Corieli Institute for Medical Re in situ hybridization using a complementary DNA clone, GRB-1. search, Camden, NJ). Human chromosomes or chromosome regions The gene for p85<*is at chromosome region 5ql3, perhaps near the retained by individual hybrids in the panel are illustrated in Fig. 1. gene encoding another receptor associated signal transducing protein, the Hybrids retaining partial chromosome 5 have also been described GTPase activating protein. previously (12). Filter Hybridization. DNA from mouse, human, and hybrid cell lines Introduction was obtained by a standard phenol-chloroform extraction procedure (10). Approximately 10 Mgof DNA were digested to completion with Skolnik et al.
    [Show full text]
  • Cytogenetic and Molecular Delineation of the Smallest Commonly Deleted Region of Chromosome 5 in Malignant Myeloid Diseases
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 5484-5488, June 1993 Medical Sciences Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases (myeloid leukemias/tumor-suppressor genes/fluorescence in situ hybridization/therapy-related leukemia) MICHELLE M. LE BEAU*, RAFAEL ESPINOSA III, WILMA L. NEUMAN, WENDY STOCK, DIANE ROULSTON, RICHARD A. LARSON, MAURI KEINANEN, AND CAROL A. WESTBROOK Section of Hematology/Oncology, The University of Chicago, Chicago, IL 60637-1470 Communicated by Janet D. Rowley, March 5, 1993 ABSTRACT Loss ofa whole chromosomeS or a deletion of nonmalignant diseases (4). Therapy-related MDS or AML its long arm (5q) is a recurring abnormality in malignant (t-MDS/t-AML) typically presents =5 years after treatment. myeloid neoplasms. To determine the location of genes on Sq Frequently, all three hematopoietic cell lines (erythroid, that may be involved in leukemogenesis, we examined the myeloid, and megakaryocytic) are involved in the myelo- deleted chromosome 5 homologs in a series of 135 patients with dysplastic process. Survival times ofpatients with t-AML are malignant myeloid diseases. By comparing the breakpoints, we usually short (median, 8 months). identified a small segment of 5q, consisting of band 5q31, that At the cytogenetic level, t-MDS/t-AML is characterized by was deleted in each patient. This segment has been termed the loss ofan entire chromosome 5 or7 or a deletion ofthe long arm critical region. Distal Sq contains a number of genes encoding of these chromosomes [del(5q)/del(7q)] (5, 6). In our recently growth factors, hormone receptors, and proteins involved in updated series of 129 consecutive patients with t-MDS/t-AML signal transduction or transcriptional regulation.
    [Show full text]
  • Chromosome 13 Introduction Chromosome 13 (As Well As Chromosomes 14, 15, 21 and 22) Is an Acrocentric Chromosome. Short Arms Of
    Chromosome 13 ©Chromosome Disorder Outreach Inc. (CDO) Technical genetic content provided by Dr. Iosif Lurie, M.D. Ph.D Medical Geneticist and CDO Medical Consultant/Advisor. Ideogram courtesy of the University of Washington Department of Pathology: ©1994 David Adler.hum_13.gif Introduction Chromosome 13 (as well as chromosomes 14, 15, 21 and 22) is an acrocentric chromosome. Short arms of acrocentric chromosomes do not contain any genes. All genes are located in the long arm. The length of the long arm is ~95 Mb. It is ~3.5% of the total human genome. Chromosome 13 is a gene poor area. There are only 600–700 genes within this chromosome. Structural abnormalities of the long arm of chromosome 13 are very common. There are at least 750 patients with deletions of different segments of the long arm (including patients with an associated imbalance for another chromosome). There are several syndromes associated with deletions of the long arm of chromosome 13. One of these syndromes is caused by deletions of 13q14 and neighboring areas. The main manifestation of this syndrome is retinoblastoma. Deletions of 13q32 and neighboring areas cause multiple defects of the brain, eye, heart, kidney, genitalia and extremities. The syndrome caused by this deletion is well known since the 1970’s. Distal deletions of 13q33q34 usually do not produce serious malformations. Deletions of the large area between 13q21 and 13q31 do not produce any stabile and well–recognized syndromes. Deletions of Chromosome 13 Chromosome 13 (as well as chromosomes 14, 15, 21 and 22) belongs to the group of acrocentric chromosomes.
    [Show full text]
  • The Role of Non-Coding Rnas in Uveal Melanoma
    cancers Review The Role of Non-Coding RNAs in Uveal Melanoma Manuel Bande 1,2,*, Daniel Fernandez-Diaz 1,2, Beatriz Fernandez-Marta 1, Cristina Rodriguez-Vidal 3, Nerea Lago-Baameiro 4, Paula Silva-Rodríguez 2,5, Laura Paniagua 6, María José Blanco-Teijeiro 1,2, María Pardo 2,4 and Antonio Piñeiro 1,2 1 Department of Ophthalmology, University Hospital of Santiago de Compostela, Ramon Baltar S/N, 15706 Santiago de Compostela, Spain; [email protected] (D.F.-D.); [email protected] (B.F.-M.); [email protected] (M.J.B.-T.); [email protected] (A.P.) 2 Tumores Intraoculares en el Adulto, Instituto de Investigación Sanitaria de Santiago (IDIS), 15706 Santiago de Compostela, Spain; [email protected] (P.S.-R.); [email protected] (M.P.) 3 Department of Ophthalmology, University Hospital of Cruces, Cruces Plaza, S/N, 48903 Barakaldo, Vizcaya, Spain; [email protected] 4 Grupo Obesidómica, Instituto de Investigación Sanitaria de Santiago (IDIS), 15706 Santiago de Compostela, Spain; [email protected] 5 Fundación Pública Galega de Medicina Xenómica, Clinical University Hospital, SERGAS, 15706 Santiago de Compostela, Spain 6 Department of Ophthalmology, University Hospital of Coruña, Praza Parrote, S/N, 15006 La Coruña, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-981951756; Fax: +34-981956189 Received: 13 September 2020; Accepted: 9 October 2020; Published: 12 October 2020 Simple Summary: The development of uveal melanoma is a multifactorial and multi-step process, in which abnormal gene expression plays a key role.
    [Show full text]
  • High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies
    Manuscript High rate of recurrent de novo mutations in developmental and epileptic encephalopathies Fadi F. Hamdan1, Candace Myers2, Patrick Cossette3,4, Philippe Lemay1, Dan Spiegelman5, Alexandre Dionne Laporte5, Christina Nassif1, Ousmane Diallo5, Jean Monlong6,7, Maxime Cadieux-Dion3,8,9, Sylvia Dobrzeniecka3, Caroline Meloche3, Kyle Retterer10, Megan T. Cho10, Jill A. Rosenfeld11, Weimin Bi11,12, Christine Massicotte1, Marguerite Miguet1, Ledia Brunga13, Brigid M. Regan14, Kelly Mo14, Cory Tam14, Amy Schneider15, Georgie Hollingsworth15, DDD Study16, David R. FitzPatrick17, Alan Donaldson18, Natalie Canham19, Edward Blair20, Bronwyn Kerr21, Andrew E. Fry22, Rhys H. Thomas23, Joss Shelagh24, Jane A. Hurst25, Helen Brittain25, Moira Blyth26, Robert Roger Lebel27, Erica H. Gerkes28, Laura Davis-Keppen29, Quinn Stein30, Wendy K. Chung31, Sara J. Dorison32, Paul J. Benke33, Emily Fassi34, Nicole Corsten-Janssen28, Erik-Jan Kamsteeg35, Frederic T. Mau-Them36,37, Ange-Line Bruel36,37, Alain Verloes38, Katrin Õunap39, Monica H Wojcik40, Dara V.F. Albert41, Sunita Venkateswaran42, Tyson Ware43, Dean Jones44, Yu-Chi Liu45,46,, Shekeeb S. Mohammad47, Peyman Bizargity11, Carlos A. Bacino11,48, Vincenzo Leuzzi49, Simone Martinelli50, Bruno Dallapiccola51, Marco Tartaglia51, Lubov Blumkin52, Klaas J. Wierenga53, Gabriela Purcarin53, James J. O'Byrne54, Sylvia Stockler54, Anna Lehman55, Boris Keren56,57, Marie-Christine Nougues58, Cyril Mignot56,57, Stéphane Auvin59,60, Caroline Nava56,57, Susan M. Hiatt61, Martina Bebin62, Yunru Shao11, Fernando Scaglia11, Seema R. Lalani11, Richard E. Frye63,64, Imad T. Jarjour65, Stéphanie Jacques66, Renee- Myriam Boucher67, Emilie Riou68, Myriam Srour69,70, Lionel Carmant1,4,71, Anne Lortie4,71, Philippe Major4,71, Paola Diadori4,71, François Dubeau5, Guy D’Anjou4,71, Guillaume Bourque6,7, Samuel F. Berkovic15, Lynette G.
    [Show full text]
  • Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
    Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
    [Show full text]
  • The Cytogenetics of Hematologic Neoplasms 1 5
    The Cytogenetics of Hematologic Neoplasms 1 5 Aurelia Meloni-Ehrig that errors during cell division were the basis for neoplastic Introduction growth was most likely the determining factor that inspired early researchers to take a better look at the genetics of the The knowledge that cancer is a malignant form of uncon- cell itself. Thus, the need to have cell preparations good trolled growth has existed for over a century. Several biologi- enough to be able to understand the mechanism of cell cal, chemical, and physical agents have been implicated in division became of critical importance. cancer causation. However, the mechanisms responsible for About 50 years after Boveri’s chromosome theory, the this uninhibited proliferation, following the initial insult(s), fi rst manuscripts on the chromosome makeup in normal are still object of intense investigation. human cells and in genetic disorders started to appear, fol- The fi rst documented studies of cancer were performed lowed by those describing chromosome changes in neoplas- over a century ago on domestic animals. At that time, the tic cells. A milestone of this investigation occurred in 1960 lack of both theoretical and technological knowledge with the publication of the fi rst article by Nowell and impaired the formulations of conclusions about cancer, other Hungerford on the association of chronic myelogenous leu- than the visible presence of new growth, thus the term neo- kemia with a small size chromosome, known today as the plasm (from the Greek neo = new and plasma = growth). In Philadelphia (Ph) chromosome, to honor the city where it the early 1900s, the fundamental role of chromosomes in was discovered (see also Chap.
    [Show full text]
  • Phenotype-Karyotype Correlation in Patientstrisomic
    J Med Genet: first published as 10.1136/jmg.23.4.310 on 1 August 1986. Downloaded from Journal of Medical Genetics 1986, 23, 310-315 Phenotype-karyotype correlation in patients trisomic for various segments of chromosome 13 SUGANDHI A THARAPEL*, RAYMOND C LEWANDOWSKIt, AVIRACHAN T THARAPEL*, AND R SID WILROY JR* From *the Division of Genetics, Department of Pediatrics, University of Tennessee Center for the Health Sciences, Memphis, Tennessee; and tDriscoll Foundation Children's Hospital, Corpus Christi, Texas, USA. SUMMARY Analysis of clinical and cytogenetic findings taken from 62 published cases of partial trisomies of chromosome 13 showed that 15 had partial trisomy for the proximal long arm and 47 had trisomy for the distal long arm. Persistence of fetal haemoglobin (Hb F), increased projections of polymorphonuclear leucocytes (PMN), depressed nasal bridge, cleft lip/palate, and clinodactyly were more frequent in patients with proximal trisomy 13. In the distal trisomy group, the common features included haemangioma, bushy eyebrows, long curled eyelashes, prominent nasal bridge, long philtrum, thin upper lip, highly arched palate, and hexadactyly. In addition, several other features were common to both the groups, often showing inconsistency even when the same segment was in trisomy. The influence of the second aneusomy as the most likely cause for such inconsistent and overlapping phenotypes is discussed in view of the fact that 42 of 62 cases were derived from a balanced translocation carrier parent. During the past few years, our knowledge regarding parameters of complete trisomy 13 syndrome, malformation syndromes resulting from partial dupli- namely increased nuclear projections of poly- cations and deletions of chromosomes has increased morphonuclear leucocytes (PMN) to the 13q12 considerably.
    [Show full text]